PBG BioPharma Inc. announces its lead drug candidate ProZ001 is being used in a groundbreaking phase II, randomized, double-blind, placebo-controlled, cross-over trial

PBG BioPharma Inc. Announces the launch of a Phase 2/3 Clinical Trial on its Cannabinoid-based Drug Product ProZ-001 as an Adjunctive Therapy for Acute Bipolar Depression

PBG BioPharma Inc. Successfully Files Cannabinoid Master Drug File to Health Canada